Product image of Glypvilo (Vildagliptin) supplied by GNH India

Glypvilo

Active Ingredient:
Vildagliptin
Origin:
EU

Glypvilo (Vildagliptin)

Glypvilo is a prescription medication that contains the active ingredient vildagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, supplied in oral tablet form for use in the European Union. It belongs to the antidiabetic (oral hypoglycemic) therapeutic class and works by enhancing the body’s own insulin response to glucose.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glypvilo is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet and exercise. It may be used alone or in combination with other antidiabetic agents.

  • Improves glycemic control in adults with type 2 diabetes.
  • Can be combined with metformin when monotherapy is insufficient.
  • May be added to sulfonylureas to achieve target HbA1c levels.
  • Used when lifestyle modifications alone do not maintain adequate blood glucose.
  • Considered for patients who prefer oral therapy over injectable options.

Side Effects

Side effects of Glypvilo vary in frequency and severity. Most are mild and transient, while a few require medical attention.

Common

  • Upper respiratory tract infection
  • Headache
  • Dizziness
  • Nausea
  • Diarrhea
  • Joint pain

Serious

  • Pancreatitis (severe abdominal pain)
  • Severe allergic reactions (rash, swelling, difficulty breathing)
  • Hepatic dysfunction (elevated liver enzymes)
  • Hypoglycemia when combined with insulin or sulfonylureas

Precautions & Warnings

Before starting Glypvilo, certain health considerations should be reviewed to ensure safe use.

  • Assess renal function; dose adjustment may be needed in impaired kidneys.
  • Monitor liver enzymes periodically during therapy.
  • Use caution in patients with a history of pancreatitis.
  • Evaluate cardiovascular status, as some patients may experience fluid retention.
  • Discuss pregnancy and breastfeeding plans with a healthcare professional.
  • Review any history of allergic reactions to DPP‑4 inhibitors.

Avoid Interactions

Glypvilo can interact with several medications, influencing its effectiveness or safety profile.

Avoid

  • Strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase vildagliptin levels.
  • Concurrent use with other DPP‑4 inhibitors.
  • High-dose insulin or sulfonylureas without dose adjustment due to hypoglycemia risk.

Use with caution

  • Diuretics, as fluid balance changes may affect blood glucose.
  • Anticoagulants, monitoring for any alteration in INR.
  • Rifampin, which may reduce vildagliptin exposure.
  • NSAIDs, for potential renal function impact.

Frequently Asked Questions

Glypvilo selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which increases endogenous incretin levels and enhances glucose‑dependent insulin secretion while reducing glucagon release.

Glypvilo may be prescribed as monotherapy for type 2 diabetes when diet and exercise alone do not achieve glycemic targets, but a healthcare provider will determine the appropriate regimen.

The pregnancy category for Glypvilo is listed as unknown; therefore, it should only be used during pregnancy if the potential benefits justify the potential risks and after consulting a physician.

Common side effects include upper respiratory tract infection, headache, dizziness, nausea, diarrhea, and joint pain. These are usually mild and transient.

Serious reactions such as signs of pancreatitis (severe abdominal pain), severe allergic responses (rash, swelling, breathing difficulty), hepatic dysfunction, or unexplained hypoglycemia require urgent medical evaluation.

Renal function should be assessed before initiating therapy and periodically thereafter; dose adjustments may be necessary for patients with moderate to severe renal impairment.

Yes, Glypvilo is often combined with metformin to improve glycemic control when metformin alone does not achieve target HbA1c levels.

Avoid concurrent use with strong CYP3A4 inhibitors, other DPP‑4 inhibitors, and high doses of insulin or sulfonylureas without dose adjustment due to increased hypoglycemia risk.

Periodic monitoring of liver enzymes is recommended, especially in patients with pre‑existing liver disease or those taking other hepatotoxic medications.

No, Glypvilo is a prescription‑only medication and must be prescribed by a qualified healthcare professional.

If a dose is missed, take it as soon as remembered unless it is close to the time of the next scheduled dose; do not double the dose. Consult a healthcare provider for personalized advice.

Use Glypvilo with caution in patients with a history of pancreatitis, and monitor closely for any recurrence of symptoms.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT